AI Article Synopsis

Article Abstract

Background: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI).

Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA). The primary endpoint was endovenous heat-induced thrombosis (EHIT) class ≥ II.

Results: Eleven studies encompassing 2738 patients and 3147 truncal veins were included. The pooled EHIT ≥ II was 1.37% (95% CI: 0.57-3.28). Meta-regression identified an association between linear endovenous energy density (LEED) applied at the saphenofemoral junction (SFJ) and EHIT ≥ II outcomes (β = 0.011, P < 0.01). The pooled medium-term great saphenous vein (GSV) occlusion was 97.59% (95% CI: 94.89-98.88). The pooled and crude deep vein thrombosis (DVT) and pulmonary embolism (PE) estimates were 0.97% (95% CI: 0.64-1.47) and 0.04%. The comparative analysis regarding GSV occlusion, odds ratio (OR) 3.26 (95% CI: 0.76-13.97) and refluxing anterior accessory saphenous vein (AASV), risk ratio (RR) 0.45 (95% CI: 0.11-1.77) suggested a nonstatistically significant trend favoring fEVLA. Nonstatistically significant differences were identified in terms of EHIT ≥ II between the techniques, RR 1.00(95% CI: 0.18-5.53). Statistically significant differences favoring fEVLA were identified in terms of proximal groin recurrence RR 0.35 (95% CI: 0.16-0.80) and stump length (mean difference) MD -7.23 (95% CI: -11.59to-2.88).

Conclusion: This review has demonstrated the safety of fEVLA while also suggesting a potentially improved efficacy of fEVLA over sEVLA in terms of proximal groin recurrence. Moreover, the trend indicating fEVLA's superiority in terms of GSV occlusion and the occurrence of new-onset AASV reflux merits further research.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.avsg.2024.12.041DOI Listing

Publication Analysis

Top Keywords

flush endovenous
8
endovenous laser
8
laser ablation
8
ablation fevla
8
fevla treatment
8
venous insufficiency
8
systematic review
8
treatment lower
4
lower limb
4
limb venous
4

Similar Publications

Objective: The aim of this study was to compare anterior accessory saphenous vein (AASV) reflux after standard endovenous laser ablation (EVLA) vs. flush EVLA (fEVLA) of the great saphenous vein (GSV).

Methods: This was as randomised, single blind, controlled trial (Dutch Trial Register, NL5283).

View Article and Find Full Text PDF

Background: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI).

Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA).

View Article and Find Full Text PDF

Blood flow from the saphenofemoral junction(SFJ) tributaries may cause recurrence of varicose veins. Flush occlusion is defined as the total occlusion of the great saphenous vein(GSV) right to the saphenofemoral junction. The purpose of this study was to evaluate the efficacy and safety of flush endovenous thermal ablation with saphenofemoral junction tributary occlusion.

View Article and Find Full Text PDF

Background: Heterogeneity regarding dosimetry and reporting of endovenous laser ablation (EVLA) mandates the development of a standardized protocol. This study presents the mid-term results of EVLA with 1940 nm-laser and radial-fibre, supported by a four-zone dosimetry tool.

Materials And Methods: Four anatomical dosimetry zones for great saphenous veins (GSV) and two for small saphenous veins (SSV) were defined with set power levels.

View Article and Find Full Text PDF

Objective: Postablation deep vein thrombosis (DVT) represents a potentially serious complication after Varithena polidocanol endovenous microfoam (PEM) ablation. The following primary outcomes were assessed: whether (1) adjunctive apixaban anticoagulation or (2) mechanical deep venous system (DVS) saline flushing could decrease saphenofemoral junction (SFJ) thrombus extension (postablation superficial thrombus extension [PASTE]) and/or DVT compared with compression alone, after great saphenous vein (GSV) PEM ablation.

Methods: Varithena 1% PEM ablation patients were randomized to (1) SFJ compression, (2) compression and DVS saline flushing, or (3) compression, DVS saline flushing, and 5 days of postprocedural 5 mg oral apixaban anticoagulation twice daily.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!